Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria
拉武利珠单抗（每 8 周一次）和依库珠单抗（每 2 周一次）治疗阵发性睡眠性血红蛋白尿症的患者偏好及生活质量影响
期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0237497
Peipert, John Devin; Kulasekararaj, Austin G; Gaya, Anna; Langemeijer, Saskia M C; Yount, Susan; Gonzalez-Fernandez, F Ataulfo; Ojeda Gutierrez, Emilio; Martens, Christa; Sparling, Amy; Webster, Kimberly A; Cella, David; Tomazos, Ioannis; Ogawa, Masayo; Piatek, Caroline I; Wells, Richard; Sicre de Fontbrune, Flore; Röth, Alexander; Mitchell, Lindsay; Hill, Anita; Kaiser, Karen
